secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0001104659-25-026142
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio reports Q4 revenue $17.6M (+4% YoY); guides FY2025 revenue $85-88M (+23-27%)
--------------------------------------------------------------------------------

- FY2024 revenue $69.3M (+19% YoY); Q4 revenue $17.6M (+4% YoY) missed expectations due to transient disruptions.
- FY2024 net loss narrowed to $37.8M from $46.7M in 2023; Q4 net loss $9.2M vs $12.9M a year ago.
- FY2025 revenue guidance $85-88M (23-27% growth); Q1 2025 revenue expected $17-18M (2-8% growth).
- Operating expenses step down Q3 to Q4; management targets 2025 OpEx flat vs 2024.
- OviTex IHR product for inguinal hernia repair launched mid-April 2024, sold over 1,200 units in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465925026142/0001104659-25-026142-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465925026142/tm259858d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-026142

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer